# Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma

> **NCT04926532** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04926532
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926532, "Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04926532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*